Welcome

4SC is listed on the Frankfurt Stock Exchange (Prime Standard: VSC), Germany.

4SC researches and develops innovative, orally administered smallmolecule drugs for autoimmune diseases and cancer – indications with a high unmet medical need. The aim is for these targeted therapies to provide better efficacy and a lower side-effect profile than existing treatments and to offer greater benefits and new hope for patient groups that have been specifically selected for treatment. Thanks to its balanced clinical pipeline and continuous research into new, value-creating programmes, 4SC is evolving into an attractive partner for pharmaceutical and global biotechnology companies.

By People. With People. For People.